About Fibrosis-Inflammation Lab
Fibrosis-Inflammation Lab is an independent knowledge hub for researchers working on fibrosis and inflammation drug discovery. Learn about our editorial policy, coverage areas, and disclosures.
Our Mission
Fibrosis-Inflammation Lab is a practical knowledge hub for researchers advancing drug discovery in fibrosis and inflammation. We deliver neutral, evidence-based coverage of preclinical models, biomarkers, signaling pathways, and clinical landscapes — grounded exclusively in peer-reviewed literature and publicly disclosed clinical trial data.
About Our Editorial Team
This site is operated by an editorial team of researchers and science writers specializing in fibrosis and inflammation. Drawing on hands-on experience with liver, lung, renal, and cardiac fibrosis models and associated biomarkers, we aim to organize information at a granularity that supports real research decisions.
Coverage Areas
- •Liver fibrosis (MASH, cirrhosis, HCV-related) and models (AMLN, GAN, STAM, CCl4, etc.)
- •Pulmonary fibrosis (IPF, PPF) and bleomycin-induced models
- •Renal fibrosis (CKD, diabetic nephropathy) and UUO / adenine-induced models
- •Cardiac fibrosis (HFpEF, heart failure) and pressure overload / AngII models
- •ECM turnover markers, ELF, FibroScan, and non-invasive biomarkers
- •Key signaling pathways: TGF-β/Smad, YAP/TAZ, PDGF/FGF, Notch, Wnt
Editorial Policy
- ✓All articles are built exclusively on public sources: peer-reviewed publications, conference abstracts, publicly disclosed clinical trial data, and official regulatory materials.
- ✓We never use internal, customer, or otherwise confidential information.
- ✓Content is produced through AI-assisted drafting combined with domain-expert review, aiming to balance accuracy and readability.
- ✓Articles are reviewed periodically; significant updates are marked with an explicit updated date.
- ✓Corrections and update requests are welcome via our contact form.
Connect and Stay Updated
We share new articles on LinkedIn and X. Subscribe to our newsletter for weekly highlights on the topics that matter for fibrosis drug discovery.
Disclosure
This site is independently operated and does not represent any specific company or institution. While our editorial team includes active researchers in fibrosis, article content is independent of any affiliated organization. If we introduce sponsored content, CRO partnerships, or advertising in the future, such placements will be clearly disclosed on the affected pages.